Magnolia Medical Technologies develops, manufactures and markets innovative blood collection devices that significantly improve the accuracy of critical laboratory tests. As a company we are focused on establishing a new standard for sepsis testing accuracy to drive antibiotic stewardship, improve patient safety, impact key quality outcomes and significantly reduce healthcare costs. Magnolia’s flagship commercial product, Steripath® (Initial Specimen Diversion Device®), is the only FDA-cleared device indicated to reduce blood culture contamination which causes false positive sepsis test results. Steripath has been evaluated exhaustively in 14 clinical studies, including 5 peer-reviewed publications, and has demonstrated sustained reductions in contamination of up to 92%. Steripath has been clinically adopted by leading academic institutions, government military & VA medical centers and large & small community hospitals across the country -- successfully reducing the risks of false-positive sepsis results for over 1 million patients. Magnolia has developed a wide range of products to significantly improve diagnostic specimen quality aimed at directly and dramatically increasing diagnostic accuracy for critical laboratory tests. The company’s intellectual property portfolio includes more than 70 issued patents with more than 50 additional patent applications pending. For more information, visit www.magnolia-medical.com ​

Key drugs I ran trials for:• ADCETIRS (SGN-35)• IMBRUVICA (Ibrutinib)• AUY-922• IPI-145

.